Can CAR-T Cell Therapy Transform Lupus Nephritis Care? With Brad Rovin, MD

The treatment of lupus nephritis has long been challenged by profound disease heterogeneity and incomplete responses to standard immunosuppressive therapies. Despite recent advances and newly approved agents, many patients still fail to achieve complete remission. Against this backdrop, the emergence of CAR-T cell therapy represents a potentially transformative step, rooted in the field’s broader shift toward precision medicine and deeper immune modulation.

In an interview with HCPLive at the World Congress of Nephrology (WCN) Conference in Yokohama, Japan, Brad Rovin, MD, explains how the field has historically relied on broadly acting immunosuppressive approaches, such as high-dose cyclophosphamide or mycophenolate, which “treat everything” but fail to account for the biological variability across patients. He says that this one-size-fits-all strategy is increasingly being replaced by efforts to tailor therapy more precisely, particularly as it has become clear that more than half of patients do not achieve complete clinical remission with existing options.

“I think with the idea of using something like a CAR-T cell, we borrow a lot of things from oncology, there's no question about it,” he said. “The idea was, could we affect the immune system in a way that renders it less likely to attack in an autoimmune way for some prolonged period of time? I'm hesitant to use the word cure, because I don't know that we've established cure yet. I think the CAR-T data show that we can, in some patients, achieve a prolonged drug free response. Whether that is a cure in some people, we'll see.”

A key differentiator, Rovin explains, lies in the depth and breadth of B-cell targeting. Unlike conventional anti-CD20 therapies like obinutuzumab (Gazyva), which target a narrower subset of B cells, CAR-T therapies directed at CD19 affect a broader range of the B-cell lineage, including antibody-producing populations. He highlights that CAR-T therapy also appears to induce more complete depletion within lymphoid tissues, including germinal centers, which may be critical for sustained disease control and may go beyond what is achieved with current therapies.

He describes the most striking findings to date as reports of sustained clinical remission lasting up to 4 years without ongoing immunosuppression. However, he emphasizes that these results are not universal, and the therapy carries significant risks, including profound immunosuppression and potential toxicities.

Looking ahead, Rovin stresses the importance of careful patient selection, transparent communication, and continued clinical investigation. While CAR-T therapy may represent a paradigm shift in lupus care, defining its long-term role and balancing its promise with its risks will be essential as the field moves forward.

“I think now it's up to us to continue the investigations, which are ongoing, and now trials are enrolling pretty well and and try to sort these issues out, but like any new therapy, there's going to be bumps, and I think that this is important to think about when we talk to our patients and families about this,” he said.

Editors’ Note: Relevant disclosures for Rovin include Biogen, GSK, Genentech/Roche, BMS, Travere, Alexion, Novartis, AstraZeneca, Otsuka, Calliditis, and others.

References

1. Brooks A. FDA Approves Obinutuzumab (Gazyva) for Lupus Nephritis. RheumatologyLive. October 20, 2025. Accessed March 29, 2026. https://www.rheum-live.com/view/fda-approves-obinutuzumab-gazyva-for-lupus-nephritis

2. Musa R, Rout P, Qurie A. Lupus Nephritis. StatPearls. January 16, 2025. Accessed March 29, 2026. https://www.ncbi.nlm.nih.gov/books/NBK499817/